Exelixis
EXEL
£26.98
Share price
2.47%
Change (1 day)
49.54%
Change (1 year)
Categories
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.
Revenue for Exelixis (EXEL)
Revenue in 2024 (TTM): £1.69 Billion
According to Exelixis's latest financial reports the company's current revenue (TTM 
) is £1.65 Billion. an increase over the revenue in the year 2023 that were of £1.43 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Exelixis from 2000 to 2024
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2024 | £1.72 B | 20.3% |
| 2023 | £1.43 B | 7.88% |
| 2022 | £1.33 B | 25.27% |
| 2021 | £1.06 B | 46.73% |
| 2020 | £0.72 B | -1.83% |
| 2019 | £0.73 B | 9.72% |
| 2018 | £0.67 B | 100.91% |
| 2017 | £0.33 B | 115.77% |
| 2016 | £0.15 B | 518.57% |
| 2015 | £25.08 M | 55.52% |
| 2014 | £16.12 M | -15.1% |
| 2013 | £18.99 M | -35.29% |
| 2012 | £29.35 M | -84.25% |
| 2011 | £0.18 B | 55.46% |
| 2010 | £0.11 B | 27.82% |
| 2009 | £93.78 M | 16.62% |
| 2008 | £80.41 M | 40.79% |
| 2007 | £57.11 M | 13.39% |
| 2006 | £50.37 M | 14.36% |
| 2005 | £44.04 M | 59.99% |
| 2004 | £27.53 M | -4.44% |
| 2003 | £28.81 M | 4.23% |
| 2002 | £27.64 M | -2.26% |
| 2001 | £28.28 M | 70.49% |
| 2000 | £16.58 M |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 | £30.69 B | 1,752.75% | 🇬🇧 UK |
 | £36.64 B | 2,111.48% | 🇫🇷 France |
 | £49.02 B | 2,858.82% | 🇺🇸 USA |
 | £36.90 B | 2,127.14% | 🇺🇸 USA |
 | £25.53 B | 1,441.20% | 🇺🇸 USA |
 | £67.86 B | 3,995.59% | 🇺🇸 USA |
 | £48.61 B | 2,833.83% | 🇺🇸 USA |
 | £8.33 M | -99.50% | 🇺🇸 USA |
 | £72.06 M | -95.65% | 🇺🇸 USA |